In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (NASDAQ: OCUL), with a price target of $10. The company’s shares opened today at $6.76.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.9% and a 39.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $13.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11 and a one-year low of $3.30. Currently, Ocular Therapeutix has an average volume of 327.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
